{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:15:14Z","timestamp":1761844514912},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2407-14-965","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T06:47:54Z","timestamp":1434610074000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer"],"prefix":"10.1186","volume":"14","author":[{"given":"Javier","family":"Martinez-Useros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Rodriguez-Remirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurea","family":"Borrero-Palacios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arancha","family":"Cebrian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Gomez del Pulgar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"del Puerto-Nevado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Vega-Bravo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Puime-Otin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Zazo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Senin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J","family":"Fernandez-Ace\u00f1ero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria S","family":"Soengas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus","family":"Garcia-Foncillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,16]]},"reference":[{"issue":"5","key":"5144_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"JSI Ferlay","year":"2014","unstructured":"Ferlay JSI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: Cancer incidence and mortality worldwide: IARC Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014, 136 (5): E359-386.","journal-title":"Int J Cancer"},{"issue":"27","key":"5144_CR2","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1200\/JCO.2006.09.8467","volume":"25","author":"E Diaz-Rubio","year":"2007","unstructured":"Diaz-Rubio E, Tabernero J, Gomez-Espana A, Massuti B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, Reina JJ, Maurel J, Gonz\u00e1lez-Flores E, Aparicio J, Rivera F, Losa F, Aranda E: Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol. 2007, 25 (27): 4224-4230. 10.1200\/JCO.2006.09.8467.","journal-title":"J Clin Oncol"},{"issue":"12","key":"5144_CR3","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","volume":"26","author":"J Cassidy","year":"2008","unstructured":"Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirz\u00e9n F, Saltz L: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008, 26 (12): 2006-2012. 10.1200\/JCO.2007.14.9898.","journal-title":"J Clin Oncol"},{"issue":"27","key":"5144_CR4","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1200\/JCO.2006.09.2684","volume":"25","author":"R Porschen","year":"2007","unstructured":"Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, AIO Colorectal Study Group: Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol. 2007, 25 (27): 4217-4223. 10.1200\/JCO.2006.09.2684.","journal-title":"J Clin Oncol"},{"issue":"6","key":"5144_CR5","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/sj.bjc.6603011","volume":"94","author":"J Souglakos","year":"2006","unstructured":"Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis Ch, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V: FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006, 94 (6): 798-805. 10.1038\/sj.bjc.6603011.","journal-title":"Br J Cancer"},{"issue":"1","key":"5144_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3816\/CCC.2004.n.009","volume":"4","author":"K Jordan","year":"2004","unstructured":"Jordan K, Kellner O, Kegel T, Schmoll HJ, Grothey A: Phase II trial of capecitabine\/irinotecan and capecitabine\/oxaliplatin in advanced gastrointestinal cancers. Clin Colorectal Cancer. 2004, 4 (1): 46-50. 10.3816\/CCC.2004.n.009.","journal-title":"Clin Colorectal Cancer"},{"issue":"9582","key":"5144_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0140-6736(07)61086-1","volume":"370","author":"M Koopman","year":"2007","unstructured":"Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007, 370 (9582): 135-142. 10.1016\/S0140-6736(07)61086-1.","journal-title":"Lancet"},{"issue":"6","key":"5144_CR8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/sj.bjc.6605595","volume":"102","author":"R Zarate","year":"2010","unstructured":"Zarate R, Rodriguez J, Bandres E, Patino-Garcia A, Ponz-Sarvise M, Viudez A, Ramirez N, Bitarte N, Chopitea A, Gacia-Foncillas J: Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer. 2010, 102 (6): 987-994. 10.1038\/sj.bjc.6605595.","journal-title":"Br J Cancer"},{"issue":"9","key":"5144_CR9","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","volume":"11","author":"K Muro","year":"2010","unstructured":"Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K: Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study). Lancet Oncol. 2010, 11 (9): 853-860. 10.1016\/S1470-2045(10)70181-9.","journal-title":"Lancet Oncol"},{"issue":"3","key":"5144_CR10","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/bjc.1998.58","volume":"77","author":"WJ Jansen","year":"1998","unstructured":"Jansen WJ, Hulscher TM, van Ark-Otte J, Giaccone G, Pinedo HM, Boven E: CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. Br J Cancer. 1998, 77 (3): 359-365. 10.1038\/bjc.1998.58.","journal-title":"Br J Cancer"},{"key":"5144_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/1471-2407-9-339","volume":"9","author":"I Kostopoulos","year":"2009","unstructured":"Kostopoulos I, Karavasilis V, Karina M, Bobos M, Xiros N, Pentheroudakis G, Kafiri G, Papakostas P, Vrettou E, Fountzilas G: Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy. BMC Cancer. 2009, 9: 339-10.1186\/1471-2407-9-339.","journal-title":"BMC Cancer"},{"issue":"16","key":"5144_CR12","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2007.15.5580","volume":"26","author":"MS Braun","year":"2008","unstructured":"Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MK, Seymour MT: Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol. 2008, 26 (16): 2690-2698. 10.1200\/JCO.2007.15.5580.","journal-title":"J Clin Oncol"},{"issue":"3","key":"5144_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/gcc.2870050309","volume":"5","author":"M von Lindern","year":"1992","unstructured":"von Lindern M, Breems D, van Baal S, Adriaansen H, Grosveld G: Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia. Genes Chromosomes Cancer. 1992, 5 (3): 227-234. 10.1002\/gcc.2870050309.","journal-title":"Genes Chromosomes Cancer"},{"key":"5144_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/1471-2407-11-234","volume":"11","author":"A Datta","year":"2011","unstructured":"Datta A, Adelson ME, Mogilevkin Y, Mordechai E, Sidi AA, Trama JP: Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer. BMC Cancer. 2011, 11: 234-10.1186\/1471-2407-11-234.","journal-title":"BMC Cancer"},{"issue":"24","key":"5144_CR15","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1038\/onc.2011.2","volume":"30","author":"LM Privette Vinnedge","year":"2011","unstructured":"Privette Vinnedge LM, McClaine R, Wagh PK, Wikenheiser-Brokamp KA, Waltz SE, Wells SI: The human DEK oncogene stimulates beta-catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene. 2011, 30 (24): 2741-2752. 10.1038\/onc.2011.2.","journal-title":"Oncogene"},{"issue":"2","key":"5144_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0304-3835(00)00462-6","volume":"156","author":"RA Kroes","year":"2000","unstructured":"Kroes RA, Jastrow A, McLone MG, Yamamoto H, Colley P, Kersey DS, Yong VW, Mkrdichian E, Cerullo L, Leestma J, Moskal JR: The identification of novel therapeutic targets for the treatment of malignant brain tumors. Cancer Lett. 2000, 156 (2): 191-198. 10.1016\/S0304-3835(00)00462-6.","journal-title":"Cancer Lett"},{"issue":"19","key":"5144_CR17","first-page":"4990","volume":"59","author":"N Kondoh","year":"1999","unstructured":"Kondoh N, Wakatsuki T, Ryo A, Hada A, Aihara T, Horiuchi S, Goseki N, Matsubara O, Takenaka K, Shichita M, Tanaka K, Shuda M, Yamamoto M: Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res. 1999, 59 (19): 4990-4996.","journal-title":"Cancer Res"},{"issue":"16","key":"5144_CR18","doi-asserted-by":"publisher","first-page":"6405","DOI":"10.1158\/0008-5472.CAN-09-1063","volume":"69","author":"MS Khodadoust","year":"2009","unstructured":"Khodadoust MS, Verhaegen M, Kappes F, Riveiro-Falkenbach E, Cigudosa JC, Kim DS, Chinnaiyan AM, Markovitz DM, Soengas MS: Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res. 2009, 69 (16): 6405-6413. 10.1158\/0008-5472.CAN-09-1063.","journal-title":"Cancer Res"},{"issue":"42","key":"5144_CR19","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1038\/sj.onc.1208792","volume":"24","author":"C Grasemann","year":"2005","unstructured":"Grasemann C, Gratias S, Stephan H, Schuler A, Schramm A, Klein-Hitpass L, Rieder H, Schneider S, Kappes F, Eggert A, Lohmann DR: Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. Oncogene. 2005, 24 (42): 6441-6449.","journal-title":"Oncogene"},{"issue":"2","key":"5144_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cancergencyto.2007.08.014","volume":"179","author":"J Paderova","year":"2007","unstructured":"Paderova J, Orlic-Milacic M, Yoshimoto M, da Cunha Santos G, Gallie B, Squire JA: Novel 6p rearrangements and recurrent translocation breakpoints in retinoblastoma cell lines identified by spectral karyotyping and mBAND analyses. Cancer Genet Cytogenet. 2007, 179 (2): 102-111. 10.1016\/j.cancergencyto.2007.08.014.","journal-title":"Cancer Genet Cytogenet"},{"issue":"11","key":"5144_CR21","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.4161\/cc.5.11.2801","volume":"5","author":"MS Carro","year":"2006","unstructured":"Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M, Muller H: DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle. 2006, 5 (11): 1202-1207. 10.4161\/cc.5.11.2801.","journal-title":"Cell Cycle"},{"key":"5144_CR22","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/1471-2407-13-366","volume":"13","author":"L Lin","year":"2013","unstructured":"Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y, Li J, Lin Z: DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer. 2013, 13: 366-10.1186\/1471-2407-13-366.","journal-title":"BMC Cancer"},{"issue":"7","key":"5144_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1440-1827.2009.02392.x","volume":"59","author":"S Han","year":"2009","unstructured":"Han S, Xuan Y, Liu S, Zhang M, Jin D, Jin R, Lin Z: Clinicopathological significance of DEK overexpression in serous ovarian tumors. Pathol Int. 2009, 59 (7): 443-447. 10.1111\/j.1440-1827.2009.02392.x.","journal-title":"Pathol Int"},{"issue":"6","key":"5144_CR24","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1440-1827.2008.02239.x","volume":"58","author":"Q Wu","year":"2008","unstructured":"Wu Q, Li Z, Lin H, Han L, Liu S, Lin Z: DEK overexpression in uterine cervical cancers. Pathol Int. 2008, 58 (6): 378-382. 10.1111\/j.1440-1827.2008.02239.x.","journal-title":"Pathol Int"},{"issue":"8","key":"5144_CR25","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/j.1365-2362.2007.01841.x","volume":"37","author":"JK Nagpal","year":"2007","unstructured":"Nagpal JK, Das BR: Identification of differentially expressed genes in tobacco chewing-mediated oral cancer by differential display-polymerase chain reaction. Eur J Clin Invest. 2007, 37 (8): 658-664. 10.1111\/j.1365-2362.2007.01841.x.","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"5144_CR26","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nsmb1248","volume":"14","author":"MJ Gamble","year":"2007","unstructured":"Gamble MJ, Fisher RP: SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery. Nat Struct Mol Biol. 2007, 14 (6): 548-555. 10.1038\/nsmb1248.","journal-title":"Nat Struct Mol Biol"},{"issue":"22","key":"5144_CR27","doi-asserted-by":"publisher","first-page":"14309","DOI":"10.1128\/JVI.79.22.14309-14317.2005","volume":"79","author":"TM Wise-Draper","year":"2005","unstructured":"Wise-Draper TM, Allen HV, Thobe MN, Jones EE, Habash KB, Munger K, Wells SI: The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. J Virol. 2005, 79 (22): 14309-14317. 10.1128\/JVI.79.22.14309-14317.2005.","journal-title":"J Virol"},{"issue":"20","key":"5144_CR28","doi-asserted-by":"publisher","first-page":"7506","DOI":"10.1128\/MCB.00430-06","volume":"26","author":"TM Wise-Draper","year":"2006","unstructured":"Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, Wells SI: Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol. 2006, 26 (20): 7506-7519. 10.1128\/MCB.00430-06.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"5144_CR29","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/jcb.22191","volume":"107","author":"D Kim","year":"2009","unstructured":"Kim D, Kim J, Kang SS, Jin EJ: Transforming growth factor-beta3-induced Smad signaling regulates actin reorganization during chondrogenesis of chick leg bud mesenchymal cells. J Cell Biochem. 2009, 107 (4): 622-629. 10.1002\/jcb.22191.","journal-title":"J Cell Biochem"},{"issue":"18","key":"5144_CR30","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1158\/1078-0432.CCR-14-0885","volume":"20","author":"AK Witkiewicz","year":"2014","unstructured":"Witkiewicz AK, Balaji U, Knudsen E: Systematically defining single gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers. Clin Cancer Res. 2014, 20 (18): 4837-4848. 10.1158\/1078-0432.CCR-14-0885.","journal-title":"Clin Cancer Res"},{"key":"5144_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1479-5876-3-44","volume":"3","author":"V Souza","year":"2005","unstructured":"Souza V, Dong YB, Zhou HS, Zacharias W, McMasters KM: SW-620 cells treated with topoisomerase I inhibitor SN-38: gene expression profiling. J Transl Med. 2005, 3: 44-10.1186\/1479-5876-3-44.","journal-title":"J Transl Med"},{"issue":"9","key":"5144_CR32","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.bbadis.2014.06.032","volume":"1842","author":"I Cristobal","year":"2014","unstructured":"Cristobal I, Rincon R, Manso R, Madoz-Gurpide J, Carames C, Del Puerto-Nevado L, Rojo F, Garcia-Foncillas J: Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation. Biochim Biophys Acta. 2014, 1842 (9): 1823-1829. 10.1016\/j.bbadis.2014.06.032.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"5144_CR33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.4161\/cbt.11.6.14670","volume":"11","author":"WL Tan","year":"2011","unstructured":"Tan WL, Bhattacharya B, Loh M, Balasubramanian I, Akram M, Dong D, Wong L, Thakkar B, Salto-Tellez M, Soo RA, Fichtner I, Iacopetta B, Soong R: Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer. Cancer Biol Ther. 2011, 11 (6): 599-608. 10.4161\/cbt.11.6.14670.","journal-title":"Cancer Biol Ther"},{"issue":"23","key":"5144_CR34","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1093\/nar\/gkg864","volume":"31","author":"T Waldmann","year":"2003","unstructured":"Waldmann T, Baack M, Richter N, Gruss C: Structure-specific binding of the proto-oncogene protein DEK to DNA. Nucleic Acids Res. 2003, 31 (23): 7003-7010. 10.1093\/nar\/gkg864.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"5144_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gene.2004.08.029","volume":"343","author":"T Waldmann","year":"2004","unstructured":"Waldmann T, Scholten I, Kappes F, Hu HG, Knippers R: The DEK protein\u2013an abundant and ubiquitous constituent of mammalian chromatin. Gene. 2004, 343 (1): 1-9. 10.1016\/j.gene.2004.08.029.","journal-title":"Gene"},{"issue":"11","key":"5144_CR36","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1101\/gad.14.11.1308","volume":"14","author":"V Alexiadis","year":"2000","unstructured":"Alexiadis V, Waldmann T, Andersen J, Mann M, Knippers R, Gruss C: The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner. Genes Dev. 2000, 14 (11): 1308-1312.","journal-title":"Genes Dev"},{"issue":"37","key":"5144_CR37","doi-asserted-by":"publisher","first-page":"26802","DOI":"10.1074\/jbc.M600915200","volume":"281","author":"M Sammons","year":"2006","unstructured":"Sammons M, Wan SS, Vogel NL, Mientjes EJ, Grosveld G, Ashburner BP: Negative regulation of the RelA\/p65 transactivation function by the product of the DEK proto-oncogene. J Biol Chem. 2006, 281 (37): 26802-26812. 10.1074\/jbc.M600915200.","journal-title":"J Biol Chem"},{"issue":"10","key":"5144_CR38","doi-asserted-by":"publisher","first-page":"e111260","DOI":"10.1371\/journal.pone.0111260","volume":"9","author":"L Lin","year":"2014","unstructured":"Lin L, Piao J, Ma Y, Jin T, Quan C, Kong J, Li Y, Lin Z: Mechanisms underlying cancer growth and apoptosis by DEK overexpression in colorectal cancer. PLoS One. 2014, 9 (10): e111260-10.1371\/journal.pone.0111260.","journal-title":"PLoS One"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-965.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-14-965\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-965.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T22:29:17Z","timestamp":1652480957000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-14-965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["5144"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-14-965","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"14 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"965"}}